TEVA PACKAGE DESIGN K — 1980472

Application number
1980472

Registration number
TMA1254465

Type(s)
Design

Category
Trademark

CIPO Status
REGISTERED

TM5 status
LIVE/REGISTRATION/Issued and Active

The trademark application has been registered with the Office.

Filed
2019-08-14

Registered
2024-09-09

Registration Expiry Date
2034-09-09

Registered Owner
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a
6944020 Tel Aviv-Jaffa
ISRAEL

Agent
OSLER, HOSKIN & HARCOURT LLP
Suite 320, World Exchange Plaza
100 Queen Street
Ottawa,
ONTARIO K1P1J9

Documents
View documents

Index headings

TEVA
V

Vienna information (Code & Description)

5.3.11	Other leaves
A 5.3.13	Stylized leaves
A 5.3.15	Two to four leaves
26.4.2	Rectangles
A 26.4.5	One quadrilateral
26.4.12	Quadrilaterals containing one or more other geometrical figures -- Note: Including quadrilaterals containing bent or straight lines (except 26.4.11).
A 26.4.15	Quadrilaterals containing representations of animals or parts of animals' bodies or plants
A 26.4.18	Quadrilaterals containing one or more letters
26.11.1	One line or one band
A 26.11.9	Oblique lines or bands
A 26.11.12	Curved lines or bands (except a 26.11.13)
27.3.1	Letters or numerals representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object
A 27.3.11	Letters or numerals representing a plant

Goods (Nice class & Statement)

5	(1) Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of

symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations for human use; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; Pharmaceutical preparations for the treatment of circulatory system diseases and disorders; Pharmaceutical preparations for the treatment of sensory organ disorders; Pharmaceutical preparations for the treatment of urogenital organ disorders; Pharmaceutical preparations for the treatment of peripheral nervous system disorders; Pharmaceutical preparations for the treatment of neurological disorders.

Recordals (known also as Footnotes)

Owner Address Change / Changement d'adresse du propriétaire
DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2022-02-28
COMMENTS / COMMENTAIRES: Voir Preuve au dossier/See evidence on File No. 2121983

Action History

Action	Action date	Due date	Comments
Filed	2019-08-14		
Created	2019-08-15		
Formalized	2019-08-19		
Amendment to Application	2022-02-28		Owner Address Change / Voir Preuve au dossier/See evidence on File No. 2121983
Pre-Assessment Letter Sent	2022-04-12		Retired Goods or Services
Search Recorded	2024-05-10		
Examiner's First Report	2024-05-10	2024-11-10	
Approved	2024-05-27		APPROVED BY PROGRAM EX200M1
Approval Notice Sent	2024-05-27		APPROVED BY PROGRAM EX200M1
Advertised	2024-06-19		Vol.71 Issue 3634
Registration Pending	2024-09-09		

Registered	2024-09-09	2034-09-09	